769,947 Shares in CG Oncology, Inc. $CGON Purchased by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. acquired a new stake in CG Oncology, Inc. (NASDAQ:CGON) during the second quarter, Holdings Channel reports. The firm acquired 769,947 shares of the company’s stock, valued at approximately $54,705,000.

Several other institutional investors have also added to or reduced their stakes in the business. Seven Fleet Capital Management LP boosted its position in CG Oncology by 24.5% during the second quarter. Seven Fleet Capital Management LP now owns 1,886,236 shares of the company’s stock worth $134,017,000 after purchasing an additional 371,085 shares during the period. Bank of America Corp DE bought a new stake in shares of CG Oncology in the second quarter valued at approximately $69,978,000. Man Group plc purchased a new stake in shares of CG Oncology during the 2nd quarter valued at approximately $3,684,000. Jupiter Topco LLC purchased a new stake in shares of CG Oncology during the 2nd quarter valued at approximately $1,634,000. Finally, ADAR1 Capital Management LLC bought a new position in CG Oncology in the 2nd quarter worth approximately $8,431,000. 26.56% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at CG Oncology

In other news, Director James Mulay sold 24,165 shares of the stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $75.16, for a total transaction of $1,816,241.40. Following the completion of the sale, the director owned 24,165 shares of the company’s stock, valued at approximately $1,816,241.40. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Leonard E. Post sold 1,000 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $74.54, for a total transaction of $74,540.00. Following the transaction, the director directly owned 1,000 shares of the company’s stock, valued at approximately $74,540. This trade represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 38,129 shares of company stock worth $2,738,357. 4.80% of the stock is currently owned by insiders.

CG Oncology Trading Up 0.8%

CGON opened at $79.01 on Friday. The company has a market cap of $7.00 billion, a P/E ratio of -29.37 and a beta of 0.23. The business’s 50-day moving average price is $72.78 and its 200-day moving average price is $66.40. CG Oncology, Inc. has a 12 month low of $26.22 and a 12 month high of $80.97.

CG Oncology (NASDAQ:CGON) last released its earnings results on Thursday, August 6th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.24). The company had revenue of $1.16 million during the quarter, compared to the consensus estimate of $0.36 million. CG Oncology had a negative net margin of 3,602.68% and a negative return on equity of 25.20%. Equities research analysts forecast that CG Oncology, Inc. will post -3.27 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on CGON shares. Truist Financial lifted their price objective on shares of CG Oncology from $82.00 to $85.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Wedbush increased their target price on CG Oncology from $77.00 to $80.00 and gave the stock an “outperform” rating in a research report on Monday, May 11th. Piper Sandler lifted their price target on CG Oncology from $82.00 to $85.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. HC Wainwright reiterated a “buy” rating and issued a $100.00 price target on shares of CG Oncology in a research report on Wednesday, July 29th. Finally, JPMorgan Chase & Co. increased their price objective on CG Oncology from $91.00 to $96.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, CG Oncology has an average rating of “Moderate Buy” and a consensus price target of $83.18.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.